MedTrace Logo

ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer

NCT00496665 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2013-11-18

No results posted yet for this study

Summary

The purpose of this research study is to determine the safety and tolerability of the combination of Zactima with metronomic chemotherapy. Zactima is an oral anti-angiogenesis drug, which means it fights cancer by cutting off a tumor's blood supply. Thus, the drug starves the tumor by preventing the delivery of nutrients and oxygen. Metronomic chemotherapy is low dose oral chemotherapy pills which are taken daily. Unlike traditional chemotherapy, metronomic chemotherapy is thought to fight cancer like Zactima, by cutting off the blood supply to tumors. Because the dose is very low, the side effects are generally mild and very different from those with higher dose chemotherapy given by vein.

Conditions

Interventions

DRUG

Vandetanib

Taken orally once a day in 28-day cycles (the dose will vary)

DRUG

Cyclophosphamide

Metronic Chemotherapy: Low dose pills taken every day of each 28-day cycle

DRUG

Methotrexate

Metronic Chemotherapy: low dose pills taken on days 1 and 2 of each week

Sponsors & Collaborators

Principal Investigators

  • Erica Mayer, MD, MPH · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-08-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00496665 on ClinicalTrials.gov